Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512060 | 0.83 | RHEB (0.56) | RHEBMAPTKCNH2BRD4ALDH1A1 | |
| SCHEMBL7515557 | 0.82 | MGAM (0.56) | RHEBKDM4EHSD17B10PRSS12HPGD | |
| SCHEMBL7515553 | 0.82 | MGAM (0.56) | RHEBKDM4EHSD17B10PRSS12HPGD | |
| SCHEMBL7517579 | 0.81 | KDM4E (0.59) | RHEBKDM4EHSD17B10MAPTKCNH2 | |
| SCHEMBL7520505 | 0.80 | KCNH2 (0.65) | RHEBKDM4EKCNH2BRD4ALDH1A1 | |
| SCHEMBL7519324 | 0.80 | KDM4E (0.52) | RHEBKDM4EMAPTKCNH2BRD4 | |
| SCHEMBL7513237 | 0.79 | BRD4 (0.43) | RHEBKDM4EMAPTKCNH2BRD4 | |
| SCHEMBL7520453 | 0.77 | DRD2 (0.61) | RHEBKCNH2BRD4ALDH1A1 | |
| SCHEMBL7514629 | 0.77 | KCNH2 (0.46) | RHEBKDM4EMAPTKCNH2BRD4 | |
| SCHEMBL7517543 | 0.77 | PRSS12 (0.46) | KDM4EHSD17B10MAPTPRSS12BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | RHEB 1710/4885KDM4E 1936/4885HSD17B10 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.